open access

Vol 10, No 1 (2014)
Congress abstract / Abstract
Published online: 2014-03-06
Get Citation

Report of Advanced Breast Cancer Second International Consensus Conference

Katarzyna Pogoda, Renata Sienkiewicz-Kozłowska, Ewa Szombara
Onkol. Prak. Klin 2014;10(1):38-44.

open access

Vol 10, No 1 (2014)
Sprawozdania
Published online: 2014-03-06

Abstract

The Advanced Breast Cancer Second International Consensus Conference (ABC2) was held on 7th–9th November 2013. The current consensus guidelines for the management of locally advanced and metastatic breast cancer was developed. In patients with locally advanced breast cancer therapy begins with a systemic treatment, followed by surgery (generally radical mastectomy) with adjuvant radiotherapy, even in patients who achieved a complete pathological response. Adjuvant hormonal therapy is used in patients with hormone-dependent breast cancer. The validity of the early assessment of effectiveness of therapy was highlighted. Evaluation of responseis recommended after two courses of chemotherapy and further treatment should be guided depending on the response. The role of anti-HER2 targeted therapy in patients with HER2-positive locally advanced breast cancer was emphasized. Benefits of systemic treatment in patients with liver metastasis before metastasectomy, with pleural effusion before and after thoracocentesis and pleurodesis, with brain metastasis after local treatment and with locoregional recurrence after surgery were stressed.

Abstract

The Advanced Breast Cancer Second International Consensus Conference (ABC2) was held on 7th–9th November 2013. The current consensus guidelines for the management of locally advanced and metastatic breast cancer was developed. In patients with locally advanced breast cancer therapy begins with a systemic treatment, followed by surgery (generally radical mastectomy) with adjuvant radiotherapy, even in patients who achieved a complete pathological response. Adjuvant hormonal therapy is used in patients with hormone-dependent breast cancer. The validity of the early assessment of effectiveness of therapy was highlighted. Evaluation of responseis recommended after two courses of chemotherapy and further treatment should be guided depending on the response. The role of anti-HER2 targeted therapy in patients with HER2-positive locally advanced breast cancer was emphasized. Benefits of systemic treatment in patients with liver metastasis before metastasectomy, with pleural effusion before and after thoracocentesis and pleurodesis, with brain metastasis after local treatment and with locoregional recurrence after surgery were stressed.

Get Citation

Keywords

everolimus, locally advanced breast cancer, pertuzumab, metastatic breast cancer, T-DM1

About this article
Title

Report of Advanced Breast Cancer Second International Consensus Conference

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 1 (2014)

Article type

Congress abstract / Abstract

Pages

38-44

Published online

2014-03-06

Bibliographic record

Onkol. Prak. Klin 2014;10(1):38-44.

Keywords

everolimus
locally advanced breast cancer
pertuzumab
metastatic breast cancer
T-DM1

Authors

Katarzyna Pogoda
Renata Sienkiewicz-Kozłowska
Ewa Szombara

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl